Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11282908 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL1188027 | 0.75 | TYR (0.34) | TRPA1LMNA | |
| SCHEMBL16553461 | 0.73 | ADRB2 (0.39) | LMNASLC6A2CYP1A2CYP2A6 | |
| SCHEMBL16167251 | 0.73 | ACHE (0.31) | ACHE | |
| SCHEMBL27096448 | 0.73 | ESR1 (0.37) | ACHELMNASLC6A2HTR2BCYP1A2 | |
| SCHEMBL4820038 | 0.73 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL27802193 | 0.73 | — | — | |
| SCHEMBL27458562 | 0.73 | ALDH1A1 (0.33) | ACHETDP1 | |
| SCHEMBL8123180 | 0.70 | NOTUM (0.34) | ACHETRPA1LMNA | |
| SCHEMBL1074262 | 0.70 | PTGS2 (0.39) | TDP1SLC6A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028717-A1 | ARSENIC-CONTAINING LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | INV NYLON CHEMICALS AMERICAS, LLC (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023221952-A1 | CYCLIC QUATERNARY AMMONIUM SALT COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 宜昌人福药业有限责任公司 | 2023-11-23 | — | — | WO | claimed |
| CN-116041212-A | Preparation and application of difluoro olefin ether and oxime ether derivatives | 安徽农业大学 | 2023-05-02 | — | — | CN | claimed |
| CN-113354646-B | 8-aryloxy alkoxy substituted xanthine derivative and preparation method and application thereof | 南开大学 | 2022-11-15 | — | — | CN | claimed |
| CN-113603690-B | (E) -acrylic acid derivative containing xanthine-8-group and preparation method and application thereof | 南开大学 | 2022-10-25 | — | — | CN | claimed |
| CN-113603690-A | (E) -acrylic acid derivative containing xanthine-8-group and preparation method and application thereof | 南开大学 | 2021-11-05 | — | — | CN | claimed |
| CN-113354646-A | 8-aryloxy alkoxy substituted xanthine derivative and preparation method and application thereof | 南开大学 | 2021-09-07 | — | — | CN | claimed |
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | PRAXIS BIORESEARCH, INC. | 2020-12-24 | — | — | US | claimed |
| US-10662146-B2 | Prodrugs of fencamfamine | Praxis Bioresearch, LLC (US) | 2020-05-26 | — | — | US | claimed |
| US-20190330141-A1 | Compositions With A Cooling Effect | THE PROCTER & GAMBLE COMPANY | 2019-10-31 | — | — | US | claimed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| US-7053160-B1 | Metallocene monohalogenides | BASELL POLYOLEFINE GMBH (DE) | 2006-05-30 | — | — | US | claimed |
| US-6649623-B1 | Administering tetrahydropiperidine derivative; antidiabetic agents; hyperlipemia treatment; hypotensive agents | SHIONOGI & CO., LTD. (JP) | 2003-11-18 | — | — | US | claimed |
| WO-2003044029-A1 | METHOD FOR THE PRODUCTION OF ORGANODIPHOSPHONITES | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-30 | — | — | WO | claimed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | claimed |
| EP-1151993-A1 | CYCLIC AMINE DERIVATIVES AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2001-11-07 | — | — | EP | claimed |
| US-6069267-A | REACTING AT BETWEEN ABOUT-25 AND 10 DEGREE C., PHOSPHORUS TRICHLORIDE AND AN ARYL ALCOHOL TO PRODUCE A DIARYLPHOSPHORUS CHLORIDE AND HYDROGEN CHLORIDE FORMING AN INSOLUBLE SALT WITH A BASE AND IS REMOVED; REACT WITH A DIHYDRIC ARYL COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-30 | — | — | US | claimed |
| WO-1999006416-A1 | SELECTIVE SYNTHESIS OF ORGANODIPHOSPHITE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| US-4374841-A | HYPOTENSIVE, ADRENERGIC BLOCKING, AND CARDIOTONIC AGENTS; CENTRAL DEPRESSANTS | S. A. LABAZ N.V. (BE) | 1983-02-22 | — | — | US | claimed |
| US-3959332-A | N-(2-NITRO-4-ARYLOXYSULFONYL-PHENYL)-ARYLENEDIAMINES, DYES | SANDOZ LTD. (CH) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330141-A1 | Compositions With A Cooling Effect | CUTA, FABP4, EBP | ACHE 465/4885TDP1 2582/4885TRPA1 5/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | ACHE 2049/4885TDP1 858/4885TRPA1 3379/4885 |
| US-10662146-B2 | Prodrugs of fencamfamine | FEN1, PNMT, SLC19A1 | ACHE 4/4885TDP1 24/4885TRPA1 3760/4885 |
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | FOLR2, FOLR1, CYP4F2 | ACHE 1574/4885TDP1 1165/4885TRPA1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.